Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) EBIT per Share : $-0.08 (TTM As of Jan. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals EBIT per Share?

Cotinga Pharmaceuticals's EBIT per Share for the three months ended in Jan. 2020 was $-0.02. Its EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2020 was $-0.08.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Cotinga Pharmaceuticals's EBIT per Share or its related term are showing as below:

COTQF's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Cotinga Pharmaceuticals's EBIT for the three months ended in Jan. 2020 was $-0.36 Mil.

Cotinga Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Cotinga Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals EBIT per Share Chart

Cotinga Pharmaceuticals Annual Data

Trend

Apr10

Apr11

Apr12

Apr13

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

EBIT per Share

Get a 7-Day Free Trial

-0.28

-0.30

-0.31

-0.09

Cotinga Pharmaceuticals Quarterly Data
	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20
EBIT per Share	Get a 7-Day Free Trial															-0.01	-0.03	-0.02	-0.02	-0.02

Cotinga Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Cotinga Pharmaceuticals's EBIT per Share for the fiscal year that ended in Apr. 2019 is calculated as

	EBIT per Share		(A: Apr. 2019 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.055	/	21.957
=	-0.09

Cotinga Pharmaceuticals's EBIT per Share for the quarter that ended in Jan. 2020 is calculated as

	EBIT per Share		(Q: Jan. 2020 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.36	/	21.986
=	-0.02

EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.08

Cotinga Pharmaceuticals (OTCPK:COTQF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Cotinga Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1

Website

http://www.cotingapharma.com

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results

By GlobeNewswire GlobeNewswire • 04-03-2018

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire • 05-22-2019